Abbott Laboratories $ABT Shares Sold by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG decreased its stake in Abbott Laboratories (NYSE:ABT) by 50.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,035 shares of the healthcare product maker’s stock after selling 105,719 shares during the period. J. Safra Sarasin Holding AG’s holdings in Abbott Laboratories were worth $14,068,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. IMG Wealth Management Inc. grew its position in Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after acquiring an additional 167 shares in the last quarter. Anfield Capital Management LLC grew its holdings in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares in the last quarter. Delos Wealth Advisors LLC purchased a new stake in Abbott Laboratories during the 2nd quarter worth $32,000. Copia Wealth Management acquired a new position in Abbott Laboratories in the 3rd quarter worth $38,000. Finally, Curio Wealth LLC boosted its position in Abbott Laboratories by 15,250.0% in the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock valued at $42,000 after buying an additional 305 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 1.3%

Shares of NYSE:ABT opened at $108.79 on Tuesday. The company’s fifty day moving average is $124.34 and its two-hundred day moving average is $128.12. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. Abbott Laboratories has a 1-year low of $105.78 and a 1-year high of $141.23. The stock has a market capitalization of $189.18 billion, a price-to-earnings ratio of 29.25, a price-to-earnings-growth ratio of 1.78 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is currently 67.74%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ABT. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Wells Fargo & Company upped their target price on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. The Goldman Sachs Group decreased their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday. BTIG Research cut their price target on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Friday. Finally, Citigroup decreased their price objective on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.79.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.